<DOC>
	<DOCNO>NCT02118584</DOCNO>
	<brief_summary>This two-part , part 1 : open-label extension ( OLE ) part 2 : safety monitoring ( SM ) study examine efficacy safety continue etrolizumab treatment moderate severe ulcerative colitis ( UC ) participants previously enrol etrolizumab Phase II/III study . Participants moderate severe UC enrol Phase II OLE study ( GA27927 [ NCT01461317 ] ) Phase III study ( GA28948 [ NCT02163759 ] , GA28949 [ NCT02171429 ] , GA28950 [ NCT02100696 ] , GA29102 [ NCT02165215 ] , GA29103 [ NCT02136069 ] ) include . Participants Phase II OLE study Phase III study eligible willing receive etrolizumab OLE-SM study , complete 12-week safety follow-up period enrol Part 2 . Part 1 OLE-SM continue 7 year first participant enrol study . Following Part 1 , participant enter Part 2 period 92 week .</brief_summary>
	<brief_title>Study Participants With Ulcerative Colitis Previously Enrolled Etrolizumab Phase II/III Studies</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Part 1 ( Openlabel Extension ) Participants previously enrol Phase II OLE study Phase III control study meet eligibility criterion openlabel etrolizumab study describe protocol Part 2 ( Safety Monitoring ) Participants whose safety followup PML followup complete within Study GA27927 participant last dose etrolizumab July 2016 Study GA27927 eligible willing enroll Part 1 ( OLE ) Participants participate one etrolizumab Phase III study eligible willing enter Part 1 ( OLE ) Participants transfer Part 1 ( OLE ) Completion 12week safety followup prior enter . Part 1 ( Openlabel Extension ) Withdrawal consent participant compliant Phase II OLE study Phase III study Participant discontinue etrolizumab/etrolizumab placebo prior Week 10 perform Week 10 visit Phase III Studies GA28948 , GA28949 , GA29102 , GA29103 Participant discontinue etrolizumab/etrolizumab placebo prior Week 14 perform Week 14 visit Phase III Study GA28950 Any new , significant , uncontrolled condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>